Pharmacology, clinical efficacy and safety of bromfenac ophthalmic solution

Expert Review of Ophthalmology

Volumn 2, Issue 4, 2007, Pages 543-549

  Fujishima, Hiroshi ^a  

^a International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

allergic conjunctivitis; bromfenac; corneal complications; NSAIDs; ocular inflammation; ophthalmic solution

Indexed keywords

EID: 80255123996     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.4.543     Document Type: Article

References (36)

1. Hirata F, Schiffmann E, Venkatasubramanian K, Salomon D, Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc. Natl Acad. Sci. USA 77, 2533–2536 (1980).
2. Davidson FF, Dennis EA, Powell M, Glenney JR Jr. Inhibition of phospholipase A2 by “lipocortins” and calpactins. An effect of binding to substrate phospholipids. J. Biol. Chem. 262, 1698–705 (1987).
3. Guex-Crosier Y. Non-steroidal anti-inflammatory drugs and ocular inflammation. Klin. Montasl. Augenheilkd. 218, 305–308 (2001).
4. ® package insert. Senju Pharmaceutical Company, Ltd, Osaka, Japan (2003).
5. Xibrom™ (bromfenac ophthalmic solution) 0.09% prescribing information. ISTA Pharmaceuticals, Inc. (2005).
6. Wood TS, Stewart RH, Bowman RW, McCulley JP, Reaves TA Jr. Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology 95, 822–826 (1988).
7. Abelson MB, Butrus SI, Weston JH. Aspirin therapy in vernal conjunctivitis. Am. J. Ophthalmol. 95, 502–505 (1983).
8. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv. Ophthalmol. 38 (Suppl.), 141–148 (1993).
9. Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schultz N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv. Ophthalmol. 38 (Suppl.), 133–140 (1993).
10. Apt L, Voo I, Isenberg SJ. A randomized clinical trial of the nonsteroidal eyedrop diclofenac after strabismus surgery. Ophthalmology 105, 1448–1452 (1998).
11. Lembeck F, Popper H, Juan H. Release of prostaglandins by bradykinin as an intrinsic mechanism of its algesic effect. Naunyn. Schmiedebergs Arch. Pharmacol. 294, 69–73 (1976).
12. Sancilio LF, Nolan JC, Wagner LE, Ward JW. The analgesic and anti-inflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung 37, 513–519 (1987).
13. Kida T, Ogawa T, McNamara TR, Song CK, Gow JA. Evaluations of human COX-2 inhibition for amfenac, bromfenac, diclofenac and ketrolac. Proceedings of the American Society of Cataract & Refractive Surgery (ASCRS) Meeting. CA, USA (2007).
14. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270, 283–286 (1995).
15. Evett GE, Xie W, Chipman JG, Robertson DL, Simmons DL. Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. Arch. Biochem. Biophys. 306, 169–177 (1993).
16. Imai E, Miner JN, Mitchell JA, Yamamoto KR, Granner DK. Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J. Biol. Chem. 268, 5353–5356 (1993).
17. Walsh DA, Moran HW, Shamblee DA et al. Anti-inflammatory agent. 3. Synthesis and pharmacological evaluation of 2-amino-3benzoylphenylacetic acid and analogues. J. Med. Chem. 11, 1379–1388 (1984).
18. Ruiz J, Lopez M, Mila J et al. QSAR and conformational analysis of the anti-inflammatory agent amfenac and analogues. J. Comput. Aided Mol. Des. 7, 183–198 (1993).
19. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97–120 (1998).
20. Ogawa T, Kida T, Song CK, Gow JA, McNamara TR. Involvement of cycloxygenase-1 and -2 in ocular inflammation and pain using rabbit models. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. FL, USA (2007).
21. Isaka M, Inada K, Tsutsumi S et al. Ocular tissue distribution in rabbit after instillation of bromfenac sodium ophthalmic solution. Drug Metab. Pharmacokinet. 14, 32–41 (1999).
22. Ogawa T, Miyake K, McNamara TR et al. Pharmacokinetic profile of topically applied bromfenac sodium ophthalmic solution 0.1% in subjects undergoing cataract surgery. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. FL, USA, A687 (2006).
23. Shimizu H, Masuda K, Fukado Y, Usui M, Komemushi S. Clinical effect of bromfenac sodium ophthalmic solution of inflammation following intraocular lens implantation: optimal frequency of instillation. Atarashii Gannka 14, 309–316 (1997).
24. Masuda K, Fukado Y, Shimizu H, Usui M, Komemushi S. Effect of bromfenac sodium ophthalmic solution on inflammation following intraocular lens implantation. Ganka Rinsho Iho (Jpn Rev. Clin. Ophthalmol.) 91, 745–750 (1997).
25. Masuda K, Fukado Y, Shimizu H, Usui M, Komemushi S. Effect of bromfenac sodium (AHR-10282B) on postoperative inflammation – a double masked trial. Nihon Gannka Kiho 48, 560–569 (1997).
26. Sawa M, Masuda K, Usui M et al. Efficacy of bromfenac sodium ophthalmic solution for ocular surface inflammation – a double-masked controlled trial. Folia. Ophthalmol. Jpn 48, 717–724 (1997).
27. Donnenfeld ED, Holland EJ, Stewart RH et al. Topical Xibrom 0.1%, an investigational NSAID for post-cataract surgery inflammation, markedly decreases inflammation. Proceedings of the American Society of Cataract & Refractive Surgery (ASCRS) Meeting. Washington, DC, USA (2005).
28. Donnenfeld ED, Holland EJ, Stewart RH et al. Topical Xibrom™ 0.09% significantly and rapidly decreased post-cataract surgery inflammation and reduced ocular pain (E-abstract 791). Invest. Ophthalmol. Vis. Sci. 46 (2005).
29. Seward MS, Cooke DL, Grillone LR et al. Topical Xibrom™ 0.09% significantly reduced ocular pain following cataract surgery. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. FL, USA, A679 (2006).
30. Kitao N, Shimoji H, Fukuda M. Post-marketing surveillance of bromfenac sodium (Bronuck) ophthalmic solution. Atarashii Ganka 22, 1299–1308 (2005).
31. Goldschmidt P, Couturier C, Haeffner-Cavaillon N, Kazatchkine M, Herman D. Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells. Ocul. Immunol. Inflamm. 5, 11–17 (1997).
32. Miyake-Kashima M, Takano Y, Tanaka M et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J. Ophthalmol. 48, 587–590 (2004).
33. Usui M, Masuda K. Effect of bromfenac sodium (AHR-10282B) eye drops on anterioruveitis. Ganka Rinsho Iho (J. Rev. Clin. Ophthalmol.) 91, 39–44 (1997).
34. Rho DS, Soll SM, Markovitz BJ. Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. FL, USA, A5211 (2006).
35. Senju Pharmaceutical Co., Ltd www.senju.co.jp
36. ISTA Pharmaceuticals Inc. www.istavision.com